World Journal of Urology

, Volume 1, Issue 2, pp 82–85 | Cite as

ABH-antigenicity of transitional cell carcinoma of the urinary bladder in patients subjected to topical chemoprophylaxis

  • Gerhard Jakse
  • Ferdinand Hofstädter
  • Udo Engelmann
  • Günther H. Jacobi


Topical chemoprophylaxis with adriamycin was administered to 49 patients with UICC-stages pTA and PT1 (pathological stage 0 and A) of transitional cell carcinoma of the urinary bladder. Tumor specimens obtained prior to initiation of the instillation protocol were evaluated with regard to ABH-antigenicity. ABH-antigens were present in tumors of 19 patients and none of these developed muscle-infiltrating recurrences during or after intravesical chemoprophylaxis. The primary lesions of 30 patients were deleted of antigens; only 5 (16%) developed a progressive recurrence. Compared to a historical control group this is thought to be a true reduction of invasive tumor recurrences in ABH-negative tumors by adriamycin. We herein propose that ABH-antigenicity may serve as a valuable prescreening indicator for or against topical chemoprophylaxis.


Public Health Carcinoma Cell Carcinoma Tumor Recurrence Urinary Bladder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barnes R, Hadley H, Dick A, Johnston O, Dexter J (1977) Changes in grade and stage of recurrent bladder tumors. J Urol 118:117Google Scholar
  2. 2.
    Jacobi GH, Kurth K-H (1980) Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration. J Urol 124:34Google Scholar
  3. 3.
    Miller A, Mitchell JP, Brown NJ (1969) The Bristol bladder tumour registry. Br J Urol [Suppl] 41:1Google Scholar
  4. 4.
    Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123:461Google Scholar
  5. 5.
    Varkarakis MJ, Gaeta J, Moore RH, Murphy GP (1974) Superficial bladder tumour, aspects of clinical progression. Urology 4:414Google Scholar
  6. 6.
    Jones HC, Swinney J (1961) Thio-tepa in the treatment of tumours of the bladder. Lancet 2:615Google Scholar
  7. 7.
    Veenema RJ, Dean AL Jr, Uson AC, Roberts M, Longo F (1969) Thio-tepa bladder instillations: therapy and prophylaxis for superficial bladder tumours. J Urol 101:711Google Scholar
  8. 8.
    Wescott JW (1966) The prophylactic use of thio-tepa in the transitional cell carcinoma of the bladder. J Urol 96:913Google Scholar
  9. 9.
    Jacobi GH, Thüroft JW (1981) Prophylactic intravesical doxorubicin instillation after TUR of superficial transitional cell tumours: 3 years' experience. In: Oliver RTD, Hendry WF, Bloom HJG (eds) Bladder cancer, principles of combination therapy. Butterworths, London Boston, pp 85–87Google Scholar
  10. 10.
    Soloway MS (1980) The management of superficial bladder cancer. Cancer 45:1856Google Scholar
  11. 11.
    Soloway MS, Masters S (1980) Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer 46:1158Google Scholar
  12. 12.
    Alfthan O, Suominen R (1978) Intravesical therapy with adriamycin. WHO Collaborating Centre for Research and Treatment of Urinary Bladder Cancer, Stockholm, September 1978Google Scholar
  13. 13.
    Nocks BN, Nieh PT, Prout GR Jr (1979) A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa. J Urol 122:27Google Scholar
  14. 14.
    Riddle PR (1973) The management of superficial bladder tumours with intravesical epodyl. Br J Urol 45:84Google Scholar
  15. 15.
    Robinson MRG, Shetty MB, Richard B, Bastable J, Glashan RW, Smith PH (1977) Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. J Urol 118:972Google Scholar
  16. 16.
    UICC (1978) TNM-classification of malignant tumors, 3rd edn. Union Internationale Contre le Cancer, Geneva, p 79Google Scholar
  17. 17.
    Mostofi FK, Sobin LH, Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization, GenevaGoogle Scholar
  18. 18.
    Davidsohn I, Kovarik S, Ni LY (1969) Isoantigens A, B and H in benign and malignant lesions of the cervix. Arch Pathol 87:306Google Scholar
  19. 19.
    Kovarik S, Davidsohn I, Stejskal R (1968) ABO antigens in cancer. Detection with the mixed cell agglutination reaction. Arch Pathol 86:12Google Scholar
  20. 20.
    Jakse G, Hofstädter F (1978) Further experiences with the specific red cell adherence test in bladder cancer. Eur Urol 4:356Google Scholar
  21. 21.
    Jakse G, Hofstädter F, Friessnig F (1978) ABH-Antigene beim Blasentumor Stadium 0 und A. Aktuel Urol 9:15Google Scholar
  22. 22.
    DeCenzo JM, Howard P, Irish CE (1975) Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114:874Google Scholar
  23. 23.
    Lange PH, Limas C, Fraley EE (1978) Tissue blood group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 119:52Google Scholar
  24. 24.
    Newman AJ Jr, Carlton CE Jr, Johanson S (1980) Cell surface A, B or 0 blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol 124:27Google Scholar
  25. 25.
    Emmott RC, Droller MJ, Javadpour N (1981) Studies of A, B or 0 (H) surface antigen specificity: carcinoma in situ and nonmalignant lesions of the bladder. J Urol 125:32Google Scholar
  26. 26.
    Askari A, Colmenares E, Saberi A, Jarman WD (1981) Red cell surface antigen and its relationship to survival of patients with transitional cell carcinoma of the bladder. J Urol 125:182Google Scholar
  27. 27.
    Alroy J, Teramura K, Miller AW 3rd, Pauli BU, Gottesman JW, Flanagan M, Davidsohn I, Weinstein RS (1978) Isoantigens A, B and H in urinary bladder carcinomas following radiotherapy. Cancer 41:1939Google Scholar
  28. 28.
    Koss LG, Melamed MR, Ricci A, Melick WF, Kelly RE (1965) Carcinogenesis in the human urinary bladder. N Engl J Med 272:767Google Scholar
  29. 29.
    Jakse G, Hofstädter F, Marberger H (1981) Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 125:185Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Gerhard Jakse
    • 1
  • Ferdinand Hofstädter
    • 2
  • Udo Engelmann
    • 3
  • Günther H. Jacobi
    • 3
  1. 1.Urologische UniversitätsklinikInnsbruckAustria
  2. 2.Pathologisches Institut der UniversitätsklinikInnsbruckAustria
  3. 3.Urologische Klinik und Poliklinik im Klinikum der Johannes-Gutenberg-UniversitätMainzFederal Republic of Germany

Personalised recommendations